Document is current
Any future updates will be listed below
-
Authors
Todd, Christopher D.
Ijaz, Jannat
Torabi, Fereshteh
Dovgusha, Oleksandr
Bevan, Stephen
Cracknell, Olivia
Lohoff, Tim
Clark, Stephen
Argelaguet, Ricard
Pierce, Juliette
Kafetzopoulos, Ioannis
Santambrogio, Alice
Nichols, Jennifer
von Meyenn, Ferdinand
Günesdogan, Ufuk
Schoenfelder, Stefan
Reik, Wolf
-
Funding
Funding for this research was provided by:
Wellcome Trust (210754/Z/18/Z)
European Research Council (EpiCell Linage:882798, EpiCell Linage:882798, EpiCell Linage:882798)
Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0421, BBS/E/B/000C0421, BBS/E/B/000C0421)
BBSRC Flexible Talent and Mobility Account (FTMA, FTMA, FTMA)
Humboldt Foundation (Sofja Kovalevskaja Award, Sofja Kovalevskaja Award)
International Max Planck School for Genome Science
BBSRC Industrial CASE training grant (BB/W510087/1)
UK Research and Innovation (MR/T016787/1)
Wellcome Collaborative award (220379/Z/20/Z)
Wellcome Investigator Award (210754/B/18/Z)
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 18 June 2025
First Online: 18 July 2025
Declarations
:
: Use of human tissues approved by the Multi-Centre Research Ethics Committee and licensed by the Human Fertilization and Embryology Authority of the United Kingdom, under Research License R0178.
: Not applicable.
: WR is a consultant and shareholder of Biomodal. CDT, JI, SC, RAC, IK, AS, and WR are employees of Altos Labs. SS is a co-founder, shareholder, and employee of Enhanc3D Genomics. SB is an employee of GSK plc. TL is employed on a full-time basis by Forbion, a venture capital firm specializing in investment within the life sciences sector. FT, OD, OC, JP, JN, FVM, and UG declare no competing interests.
